Clinical Trial Details
| Trial ID: | L0345 |
| Source ID: | NCT00111098 |
| Associated Drug: | Darbepoetin Alfa |
| Title: | Treatment for Subjects With Chronic Kidney Disease (CKD) Not Receiving Dialysis |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Kidney Disease |
| Interventions: | DRUG: Darbepoetin Alfa |
| Outcome Measures: | Primary: The proportion of subjects on QM darbepoetin alfa dosing maintained with a mean Hb greater than or equal to 11.0 g/dL during the evaluation phase, Entire Study | Secondary: To determine Hb values over the duration of the study, Entire Study|To determine darbepoetin alfa doses over the duration of the study, Entire Study|To assess the safety of darbepoetin alfa, Entire Study |
| Sponsor/Collaborators: | Sponsor: Amgen |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE3 |
| Enrollment: | 150 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2004-03 |
| Completion Date: | 2005-11 |
| Results First Posted: | |
| Last Update Posted: | 2008-08-08 |
| Locations: | |
| URL: | https://clinicaltrials.gov/show/NCT00111098 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|